J
Jin Ji Yang
Researcher at Guangdong General Hospital
Publications - 18
Citations - 8651
Jin Ji Yang is an academic researcher from Guangdong General Hospital. The author has contributed to research in topics: Lung cancer & Population. The author has an hindex of 12, co-authored 17 publications receiving 7819 citations. Previous affiliations of Jin Ji Yang include Peking Union Medical College & The Chinese University of Hong Kong.
Papers
More filters
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean-Charles Soria,Yi-Long Wu,Kazuhiko Nakagawa,Sang We Kim,Jin Ji Yang,Myung-Ju Ahn,Jie Wang,James Chih-Hsin Yang,You Lu,Shinji Atagi,Santiago Ponce,Dae Ho Lee,Yunpeng Liu,Kiyotaka Yoh,Jianying Zhou,Xiaojin Shi,Alan Webster,Haiyi Jiang,Tony Mok +18 more
TL;DR: The IMPRESS trial as discussed by the authors evaluated the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefinib.
Journal ArticleDOI
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
Yi-Long Wu,James Chih-Hsin Yang,Dong Wan Kim,Shun Lu,Jianying Zhou,Takashi Seto,Jin Ji Yang,Noboru Yamamoto,Myung-Ju Ahn,Toshiaki Takahashi,Takeharu Yamanaka,Allison Kemner,Debasish Roychowdhury,Jolanda Paolini,Tiziana Usari,Keith D. Wilner,Koichi Goto +16 more
TL;DR: This study demonstrated clinically meaningful benefit and durable responses with crizotinib in East Asian patients with ROS1-positive advanced NSCLC and generally well tolerated, with a safety profile consistent with previous reports.
Journal ArticleDOI
Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status
She-Juan An,Zhi-Hong Chen,Jian Su,X. Zhang,Wen-Zhao Zhong,Jin Ji Yang,Qing Zhou,X.-N. Yang,Ling Huang,Ji Lin Guan,Qiang Nie,Hong hong Yan,Tony Mok,Yi-Long Wu +13 more
TL;DR: The distinct features of driver gene alterations in different subgroups based on histology and smoking status were helpful in defining patients for future clinical trials that target these genes.
Journal ArticleDOI
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Caicun Zhou,Sang We Kim,Thanyanan Reungwetwattana,Jianying Zhou,Yiping Zhang,Jianxing He,Jin Ji Yang,Ying Cheng,Se-Hoon Lee,Lilian Bu,Tingting Xu,Li Yang,Chao Wang,Ting Liu,Peter N. Morcos,You Lu,Li Zhang +16 more
TL;DR: This first phase 3 randomised trial recruiting only Asian patients to compare alectinib with crizotinib as a first-line treatment for ALK-positive non-small-cell lung cancer with 600 mg of alect inib twice per day confirmed consistency of the progression-free survival benefit with the global phase 3 ALEX study.